Quorum Review IRB

Quorum Review IRB
Name	Quorum Review IRB
Type	Institutional Review Board
Industry	Clinical research ethics review
Founded	2000s
Headquarters	United States

Quorum Review IRB

Quorum Review IRB is an independent institutional review board operating within the clinical research ecosystem, providing ethical review and oversight for human subjects research across pharmaceuticals, biotechnology, and medical device trials. It interacts with sponsors, contract research organizations, academic medical centers, and regulatory agencies to facilitate protocol approval, continuing review, and safety monitoring. The board’s operations intersect with major regulatory frameworks and influential institutions in clinical research.

Overview

Quorum Review IRB functions as a centralized IRB service used by sponsors such as Pfizer, Johnson & Johnson, Roche, Novartis, and AstraZeneca, and collaborates with academic centers including Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Stanford University School of Medicine, and University of California, San Francisco. It participates in multi-site studies supported by organizations like National Institutes of Health, Bill & Melinda Gates Foundation, Wellcome Trust, European Medicines Agency, and Food and Drug Administration. The IRB model draws comparisons with other commercial boards such as Western Institutional Review Board and Advarra, and aligns procedures with professional societies including Association for the Accreditation of Human Research Protection Programs and Public Responsibility in Medicine and Research.

Regulatory Framework and Definitions

Quorum Review IRB’s activities are governed by statutes and guidances from entities like the Department of Health and Human Services, the Office for Human Research Protections, the Federal Food, Drug, and Cosmetic Act, and international frameworks such as the Declaration of Helsinki, Council for International Organizations of Medical Sciences, and regulations from the European Commission. Definitions of human subjects research follow precedent from case law involving parties such as U.S. Supreme Court decisions and regulatory guidance referenced by agencies like Centers for Medicare & Medicaid Services and Office of Inspector General (United States Department of Health and Human Services). The IRB applies standards paralleling those articulated in guidances issued by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and policy positions from World Health Organization and National Cancer Institute.

Quorum Requirements and Composition

Quorum Review IRB composes panels drawing on expertise represented by professionals associated with institutions like Harvard Medical School, Yale School of Medicine, Columbia University, University of Pennsylvania Perelman School of Medicine, and specialty organizations such as American Medical Association, American Psychological Association, American Nurses Association, and Society for Clinical Trials. Quorum and membership criteria reflect regulatory expectations from Code of Federal Regulations provisions and oversight bodies including Institutional Biosafety Committees at centers like Cleveland Clinic and ethics committees modeled after procedures at World Health Organization. Panels include physicians, biostatisticians, ethicists, and community members drawing on experience from programs at Centers for Disease Control and Prevention, National Institutes of Health Clinical Center, and specialty hospitals such as Cleveland Clinic and Texas Children’s Hospital.

Decision-Making Processes and Voting

Decision-making at Quorum Review IRB integrates protocols for convened meetings and expedited review mechanisms consistent with precedents cited by Office for Human Research Protections and interpreted in the context of standards used by European Medicines Agency and International Conference on Harmonisation. Voting procedures mirror approaches used by institutional committees at Massachusetts General Hospital, Johns Hopkins Medicine, and commercial counterparts like Advarra, with documented minutes, conflict of interest disclosures referencing standards akin to those promulgated by Securities and Exchange Commission and institutional policies of National Institutes of Health. The IRB’s determinations—approval, modifications required, deferral, or disapproval—are recorded to satisfy audit trails for sponsors such as GlaxoSmithKline, Eli Lilly and Company, and CROs like IQVIA.

Exceptions, Waivers, and Emergency Reviews

Quorum Review IRB applies criteria for waivers of consent and emergency use consistent with regulatory provisions from Food and Drug Administration, Department of Health and Human Services, and guidance influenced by cases involving institutions such as Veterans Health Administration and research networks like Clinical and Translational Science Awards. Emergency review processes align with rapid response models used during public health crises coordinated with Centers for Disease Control and Prevention, World Health Organization, and funding partners like Wellcome Trust or Bill & Melinda Gates Foundation. Waivers for documentation or full consent consider precedent from ethical frameworks such as the Declaration of Helsinki and operational examples from multicenter trials coordinated by National Institutes of Health networks.

Implications for Research Compliance and Ethics

The IRB’s role impacts compliance efforts undertaken by sponsors and institutions including Pfizer, Roche, University of California, Los Angeles Health, Duke University School of Medicine, and Mount Sinai Health System, informing protocols for adverse event reporting, data monitoring, and participant protections modeled on guidance from Office for Human Research Protections and International Council for Harmonisation. Ethical implications touch on issues debated in literature from sources like New England Journal of Medicine, The Lancet, JAMA, Nature Medicine, and BMJ, and influence policy discussions involving legislators in bodies such as the United States Congress and regulators at European Commission. The board’s determinations affect clinical trial timelines, patient safety oversight in contexts involving oncology, cardiology, and infectious disease trials, and intersect with data privacy regimes referenced by Health Insurance Portability and Accountability Act enforcement and institutional policies at major research hospitals.

Category:Institutional review boards